Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were enrolled at 112 investigative sites, 106 in the United States and 6 in Canada, from 11 July 2002 to 20 February 2004.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects currently receiving urate-lowering therapy discontinued those urate-lowering therapies and initiated prophylactic medications before enrollment in once daily (QD) treatment groups.

Reporting Groups

	Description
Febuxostat 80 mg QD	Febuxostat 80 mg, orally, once daily for up to 52 weeks.
Febuxostat 120 mg QD	Febuxostat 120 mg, orally, once daily for up to 52 weeks.
Allopurinol 300 mg QD	Allopurinol 300 mg, orally, once daily for up to 52 weeks.

Participant Flow:   Overall Study

	Febuxostat 80 mg QD	Febuxostat 120 mg QD	Allopurinol 300 mg QD
STARTED	256	251	253
COMPLETED	168	153	187
NOT COMPLETED	88	98	66
Lost to Follow-up	25	18	21
Adverse Event	16	23	8
Gout Flare	10	28	9
Personal Reason(s)	19	13	13
Other	11	14	14
Protocol Violation	7	2	1

1.  Primary:

Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)

2.  Secondary:

Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit

3.  Secondary:

Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit

4.  Secondary:

Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit

5.  Secondary:

Percent Change From Baseline in Serum Urate Levels at Week 28.

6.  Secondary:

Percent Change From Baseline in Serum Urate Levels at Week 52.

7.  Secondary:

Percent Change From Baseline in Serum Urate Levels at Final Visit

8.  Secondary:

Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

9.  Secondary:

Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

10.  Secondary:

Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

11.  Secondary:

Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.

12.  Secondary:

Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.

13.  Secondary:

Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.

14.  Secondary:

Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.